Pericarditis as a complication of infliximab therapy in Crohn's disease

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 428-429

  Burke, J P ^a   Kelleher, B ^a   Ramadan, S ^b   Quinlan, M ^a   Sugrue, D ^a   O'Donovan, M A ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b Midlands Regional Hospital Mullingar   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LETTER; LUNG ANGIOGRAPHY; MAINTENANCE THERAPY; MALE; PERICARDITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROLOGY; ST SEGMENT ELEVATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; PERICARDITIS; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149178676     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20270     Document Type: Letter

References (3)

1. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126(1):19-31.
2. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125(1):32-39.
3. Harney S, O'Shea FD, FitzGerald O. Peptostreptococcal pericarditis complicating antitumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis. 2002; 61:653-654.